Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
38P - Survival of lung cancer: Bangladesh perspective (ID 239)
12:30 - 13:00 | Presenting Author(s): R. Parveen
Lung cancer, the most common and the leading cause of cancer death in the world, is increasingly being recognized in Bangladesh. Comprising one third of all male cancers, it is mostly presented at later stages. This study aimed at finding out the survival of lung cancer patients and also the important prognostic factors behind survival who were registered and treated in National Institute of cancer Research & Hospital.
This study was done from Jan 2012 to June 2015 at Dept. of Medical Oncology, NICRH. The lung cancer patients attending NICRH in two years (from Jan 2012 to Dec 2013) were selected. After thorough evaluation, symptomatic and supportive management as well as chemotherapy and/or radiotherapy were given on priority basis. The patients were followed up every 4–8 weekly up to survival or maximum 42 months whichever was earlier. The patients were assessed during each visit by clinical status, investigations and treatment response. All events of death were documented properly.
Out of 2264 lung patients who were registered and treated during the period of Jan'12 –Dec'13, 1067 were in contact and eligible for the study. The male female ratio was 4.2:1 (862 male and 205 female). Female patients were younger (mean age of male 58.24 years and female 52.18yrs), 80% of all cases belonged to poor and lower middle-class families with 54% illiterate and 26% had primary education. Their performance status was mostly ECOG grade 2 & 3 (>80%). Male patients were smokers (90%) and females were mostly betel nut and/or tobacco chewers (66%) and also smokers (27%). All cases were at stage III and stage IV diseases with 86% non-small cell carcinoma and 14% small cell carcinoma. About 50% patients survived six months. One year survival of all cases was 27%; female 32% and male 25%. Mean survival of male and female patients was respectively 7.82 and 16.63 months. Survival of female patients was significant (P value-0.001) and survival of younger patients (<40 years) were also significant, 10.06 months (P value-0.001).
Survival in months according to gender and age Gender Mean Survival Time (months) 95% confidence interval P-value Male 7.820 7.300–8.341 0.001 (HS) Female 16.638 14.153–19.124 Overall 8.780 8.237–9.322 Age group <=40 10.063 7.723–12.403 0.001 (HS) 41–50 9.630 8.369–10.891 51–60 9.481 8.527–10.435 61–70 7.642 6.736–8.547 >70 6.171 4.944–7.399 Overall 8.780 8.237–9.322
Lung cancer patients mostly presented at advanced stage (inoperable), with poor performance status. After supportive, symptomatic and anticancer treatment (chemotherapy and radiotherapy), one year survival of lung cancer was 27%. Female and young age <40 years patients’ survival was significantly higher than male and aged patients (>40yrs).
Clinical trial identification:
Legal entity responsible for the study:
Prof. Parveen Shahida Akhtar
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.